Efficacy, Safety, and Durability of Faricimab in Diabetic Macular Edema (DME): One-Year Results From the Phase 3 YOSEMITE and RHINE Trials

Related

• 

  Expert Panel: Faricimab and Aflibercept 8 mg in AMD

  John T. Thompson, MD

  Andrew A. Moshfeghi, MD, MBA, FASRS

  Manjot K Gill, MD, FASRS

  Christina Y Weng, MD, MBA, FASRS

  Ferhina S Ali, MD, MPH

  Ian Pearce, MB ChB BSc FRCOPHTH

  Annual Meeting Talks

  2024

• 

  Real World Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study

  Carl J Danzig, MD

  Annual Meeting Talks

  2022

• 

  New Tool for Predicting the 3-Year Risk of Vision-Threatening Diabetic Retinopathy in Patients With Type 2 Diabetes Mellitus

  Bobeck S Modjtahedi, MD

  Annual Meeting Talks

  2022